Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide

Leuk Res. 2005 Aug;29(8):967-9. doi: 10.1016/j.leukres.2005.01.007. Epub 2005 Feb 17.

Abstract

We present a 75-year-old man who was admitted to our hospital because of splenomegaly, transfusion-dependent anemia and thrombocytopenia. The diagnosis of idiopathic myelofibrosis was suggested by the bone marrow trephine biopsy, which was hypocellular with myelofibrosis. Thalidomide was started at a daily dose of 100 mg/d and increased to 400 mg/d. Within 12 weeks, thrombocytes increased to 100.000/microl, hemoglobin normalized, lasting for about 11 months. Then, thalidomide had to be discontinued because of mild polyneuropathy. A second bone marrow biopsy showed fibrosis as well as a diffuse infiltration of the bone marrow (80%) by lymphocytes with expression of CD11c, CD19, CD20, CD103. Tartrate resistant acid phosphatase test (TRAP) was also positive. Hairy cell leukemia was diagnosed and he was administered 2-chlorodeoxyadenosine (2-CDA) achieving a complete remission.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cladribine / administration & dosage
  • Cladribine / therapeutic use
  • Humans
  • Leukemia, Hairy Cell / complications*
  • Leukemia, Hairy Cell / diagnosis
  • Leukemia, Hairy Cell / drug therapy*
  • Male
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy*
  • Remission Induction
  • Thalidomide / adverse effects
  • Thalidomide / therapeutic use*
  • Treatment Outcome

Substances

  • Cladribine
  • Thalidomide